卡瑞利珠单抗免疫相关不良反应临床分析

doi:10.3760/cma.j.issn.1007-1245.2023.09.017

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (9): 1258-1262.DOI: 10.3760/cma.j.issn.1007-1245.2023.09.017

卡瑞利珠单抗免疫相关不良反应临床分析

柯金王恒石张善兰

上海市松江区中心医院肿瘤血液科，上海　201600

收稿日期:2022-10-13 出版日期:2023-05-01 发布日期:2023-05-22
通讯作者: 柯金，Email：kjondoctor@163.com

Clinical analysis of immune-related adverse events induced by camrelizumab

Ke Jin, Wang Hengshi, Zhang Shanlan

Department of Oncology/Hematology, Shanghai Songjiang Central Hospital, Shanghai 201600, China

Received:2022-10-13 Online:2023-05-01 Published:2023-05-22
Contact: Ke Jin, Email: kjondoctor@163.com

摘要/Abstract

摘要：

目的　分析卡瑞利珠单抗治疗恶性肿瘤的免疫相关不良反应（irAEs）发生情况。方法　回顾性分析2020年1月至2022年2月在上海市松江区中心医院接受卡瑞利珠单抗免疫治疗的70例恶性肿瘤患者的临床资料，其中男50例，女20例，年龄48～87岁。总结irAEs发生情况及处理方法。结果　70例患者中，发生irAEs 43例（61.4%），其中15例（21.4%）同时出现累及多个系统的irAEs。1、2级不良反应38例（54.3%），3、4级不良反应5例（7.1%），包括免疫相关性肺炎2例、结肠炎1例、心肌炎1例、皮肤反应1例，5例患者经糖皮质激素治疗后不良反应完全缓解。结论　卡瑞利珠单抗的irAEs发生率高，累及多个系统，但程度轻，3级以上irAEs发生率低。

关键词:

免疫检查点抑制剂, 卡瑞利珠单抗, 免疫相关不良反应, 免疫治疗

Abstract:

Objective　To analyze the occurrence of immune-related adverse events (irAEs) induced by camrelizumab among cancer patients. Methods　The clinical data of 70 patients with malignant tumors who received treatment of camrelizumab in Shanghai Songjiang Central Hospital from January 2020 to February 2022 were retrospectively analyzed, including 50 males and 20 females, aged 48-87 years. The incidence and treatment plans of irAEs were demonstrated. Results　Among the 70 patients, 43 cases (61.4%) developed irAEs, and of them 15 cases (21.4%) simultaneously appeared adverse events involving multiple systems. Thirty-eight patients (54.3%) had grade Ⅰ-Ⅱ irAEs; 5 patients (7.1%) had grade Ⅲ-Ⅳ irAEs, including 2 cases of immune-related pneumonitis, 1 case of colitis, 1 case of myocarditis, and 1 case of skin toxicity. The adverse reactions were completely relieved after glucocorticoid shock therapy in 5 patients. Conclusions　The incidence of irAEs induced by camrelizumab is high, and the adverse events affect multiple organs, but the symptoms are not severe. The incidence of ≥grade Ⅲ adverse reactions is low.

Key words:

Immune-checkpoint inhibitors, Camrelizumab, Immune-related adverse events, Immunotherapy

柯金王恒石张善兰.

卡瑞利珠单抗免疫相关不良反应临床分析 [J]. 国际医药卫生导报, 2023, 29(9): 1258-1262.

Ke Jin, Wang Hengshi, Zhang Shanlan.

Clinical analysis of immune-related adverse events induced by camrelizumab [J]. International Medicine and Health Guidance News, 2023, 29(9): 1258-1262.

参考文献

[1] Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade [J]. Science,2018,359(6283):1350-1355. DOI:10.1126/science.aar4060.
[2] He X, Xu C. Immune checkpoint signaling and cancer immunotherapy[J]. Cell Res, 2020, 30(8): 660-669. DOI:10.1038/s41422-020-0343-4.
[3] Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial[J]. Lancet, 2021, 398(10308): 1344-1357. DOI: 10.1016/S0140-6736(21)02098-5.
[4] Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer[J]. N Engl J Med, 2021, 384(13): 1191-1203. DOI:10.1056/NEJMoa2032125.
[5] Sharma P, Allison JP. The future of immune checkpoint therapy[J]. Science, 2015, 348(6230): 56-61. DOI:10.1126/science.aaa8172.
[6] Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: From enhancement to normalization[J]. Cell, 2018, 175(2): 313-326. DOI: 10.1016/j.cell. 2018.09.035.
[7] Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review[J]. JAMA Oncol, 2016, 2(10): 1346-1353.DOI:10.1001/jamaoncol.2016.1051.
[8] Calabrese L, Mariette X. The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy[J]. Ann Rheum Dis, 2018, 77(2): 162-164. DOI: 10.1136/annrheumdis-2017-212061.
[9] Nakahara Y, Fukui T, Shirasawa M, et al. Intracranial response to nivolumab in a patient with PD-L1-negative lung adenocarcinoma[J]. Intern Med, 2018, 57(21): 3149-3152. DOI:10.2169/internalmedicine.9884-17.
[10] Shen X, Zhang L, Li J, et al. Recent findings in the regulation of programmed death ligand 1 expression[J]. Front Immunol, 2019, 10: 1337. DOI: 10.3389/fimmu.2019.01337.
[11] Markham A, Keam SJ. Camrelizumab: first global approval[J]. Drugs, 2019, 79(12): 1355-1361. DOI:10.1007/s40265-019-01167-0.
[12] 艾罗燕,余一祎,林瑾仪,等. 真实世界中50例免疫检查点抑制剂相关严重不良反应分析[J]. 中国临床医学,2020,27(6):938-944. DOI:10.12025/j.issn.1008-6358.2020. 20201356.
[13] 张书培,杨磊,顾康生. PD-1/PD-L1抑制剂治疗晚期肿瘤患者免疫相关不良事件的预后价值[J]. 临床肿瘤学杂志,2022,27(2):109-116. DOI:10.3969/j.issn.1009-0460. 2022.02.003.
[14] Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint[J]. Immunity, 2018, 48(3): 434-452. DOI: 10.1016/j.immuni.2018.03.014.
[15] Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy[J]. Cancer Discov, 2018, 8(9): 1069-1086. DOI: 10.1158/2159-8290.CD-18-0367.
[16] Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366(26): 2443-2454. DOI:10.1056/NEJMoa1200690.
[17] Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy[J]. Science, 2013, 342(6165): 1432-1433. DOI: 10.1126/science.342.6165.1432
[18] 秦叔逵,郭军,李进.中国临床肿瘤学会(CSCO)免疫检查点抑制剂相关的毒性管理指南[M].北京:人民卫生出版社,2021: 89-95.
[19] 中国临床肿瘤学会抗肿瘤药物安全管理专家委员会,中国临床肿瘤学会免疫治疗专家委员会. 卡瑞利珠单抗致反应性皮肤毛细血管增生症临床诊治专家共识[J]. 临床肿瘤学杂志,2020,25(9):840-848. DOI:10.3969/j.issn.1009- 0460.2020.09.012.
[20] Wang F, Qin S, Sun X, et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial[J]. J Hematol Oncol, 2020, 13(1): 47-56. DOI: 10.1186/s13045-020- 00886-2.
[21] Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade[J]. N Engl J Med, 2018, 378(2): 158-168. DOI: 10.1056/NEJMra1703481.
[22] 祁玲,莫红楠,陈雪莲,等. 程序性死亡蛋白1抗体SHR-1210治疗晚期实体瘤的甲状腺功能相关不良反应[J]. 中华肿瘤杂志,2018,40(10):772-775. DOI:10.3760/cma.j.issn.0253-3766.2018.10.009.
[23] Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis[J]. JAMA Oncol, 2018, 4(2): 173-182. DOI: 10.1001/jamaoncol.2017.3064.
[24] Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the society for Immunotherapy of Cancer(SITC) Toxicity Management Working Group[J]. J Immunother Cancer, 2017, 5(1): 95. DOI: 10.1186/s40425-017-0300-z.
[25] Parlati L, Vallet-Pichard A, Batista R, et al. Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: a retrospective study[J]. J Hepatol, 2018, 69(6): 1396-1397. DOI: 10.1016/j.jhep.2018.08.014.
[26] Shieh AC, Guler E, Pfau D, et al. Imaging and clinical manifestations of immune checkpoint inhibitor -related colitis in cancer patients treated with monotherapy or combination therapy[J]. Abdom Radiol, 2020, 45(10): 3028-3035. DOI:10.1007/s00261-019-02334-3.
[27] Green HE, Nieva J. Clinical management of immune-related adverse events following immunotherapy treatment in patients with non-small cell lung cancer[J]. J Investig Med, 2021, 69(7): 1281-1286. DOI: 10.1136/jim-2021-001806.
[28] Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis[J]. JAMA Oncol, 2018, 4(12): 1721-1728. DOI: 10.1001/jamaoncol.2018. 3923.
[29] Sears CR, Peikert T, Possick JD, et al. Knowledge gaps and research priorities in immune checkpoint inhibitor-related pneumonitis: an official American Thoracic Society research statement[J]. Am J Respir Crit Care Med, 2019, 200(6): e31-e43. DOI:10.1164/rccm.201906-1202ST.
[30] Master SR, Robinson A, Mills GM, et al. Cardiovascular complications of immune checkpoint inhibitor therapy[J]. J Clin Oncol, 2019, 37(15_suppl): 2568-2568. DOI:10.1200/JCO.18.00573.
[31] Moslehi JJ, Salem JE, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor associated myocarditis[J]. Lancet, 2018, 391(10124): 933. DOI: 10.1016/S0140-6736(18)30533-6.

卡瑞利珠单抗免疫相关不良反应临床分析

Clinical analysis of immune-related adverse events induced by camrelizumab

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics